A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.